Immunome's Clinical Pipeline Meets Its First Public Accounting Moment—If the Data Exists

Immunome Inc (IMNM) is scheduled to report Q2 2026 earnings on August 12, 2026, with analysts expecting another quarterly loss as the clinical-stage biotech continues to advance its pipeline. The central question is whether the company can maintain the positive momentum from its Q1 beat and demonstrate progress in its immunotherapy programs. With the stock trading well above all major moving averages and analyst sentiment overwhelmingly bullish, investors will be watching closely for signs that IMNM's development trajectory justifies its recent rally.

Part 1: Earnings Preview

Immunome Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for oncology and infectious diseases using its proprietary human memory B cell platform. The company's lead programs target solid tumors and hematologic malignancies, positioning it in the competitive immuno-oncology space.

IMMNM is scheduled to report Q2 2026 earnings on August 12, 2026. Analysts expect an EPS loss of $-0.51 on revenue estimates that vary widely among the limited number of analysts covering the stock. The most recently reported quarter (Q1 2026) delivered an actual EPS of $-0.48, representing a significant beat. Compared to the same quarter last year when the company reported $-0.50, the current estimate of $-0.51 suggests a modest year-over-year deterioration of approximately 2%.

Three key themes define this earnings story:

Pipeline Progress and Clinical Milestones: Investors will scrutinize any updates on the company's lead programs, particularly data readouts or enrollment progress that could validate the platform and support the current valuation. Clinical-stage biotechs live and die by pipeline advancement, making any trial updates critical.

Cash Runway and Burn Rate: With consistent quarterly losses, the company's cash position and quarterly burn rate will be closely monitored. Any guidance on how long current resources can fund operations without additional capital raises will be essential for assessing near-term dilution risk.

Revenue Generation Trajectory: While still minimal, any revenue from collaborations or early partnerships could signal commercial validation of the platform. The wide range in revenue estimates (from essentially zero to $2M according to some sources) reflects uncertainty about near-term monetization.

Analyst commentary ahead of the release remains constructive, with the overwhelming majority maintaining buy ratings. The consensus reflects confidence in the company's platform technology and pipeline potential, though the wide range in price targets ($30-$40) suggests differing views on probability of success and timeline to value inflection.

Part 2: Historical Earnings Performance

Immunome has demonstrated an inconsistent earnings track record over the past four quarters, with two beats and two misses against analyst estimates. The most recent quarter (Q1 2026) showed strong performance with a +20.00% surprise, reporting $-0.48 versus the $-0.60 estimate. However, this followed two consecutive disappointing quarters where the company missed estimates by -15.38% (Q4 2025) and -14.04% (Q3 2025).

The pattern reveals significant volatility in the company's ability to meet expectations, with surprise percentages ranging from +20.00% to -15.38%. The year-ago quarter (Q2 2025) delivered a modest +3.85% beat with $-0.50 reported versus $-0.52 estimated. Looking at the absolute EPS trajectory, losses have fluctuated considerably: from $-0.50 four quarters ago to a peak loss of $-0.75 in Q4 2025, before improving to $-0.48 last quarter.

This volatility likely reflects the unpredictable nature of clinical-stage biotech operations, where quarterly expenses can swing based on trial timing, milestone payments, and R&D spending patterns. The recent Q1 beat may signal improved cost management, but the inconsistent history suggests investors should be cautious about extrapolating trends.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Based on historical reporting patterns, IMNM typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows moderate volatility, with an average absolute Day 0 move of 3.41% and Day +1 move of 3.30%. The trading ranges are wider, averaging 5.62% on Day 0 and 7.42% on Day +1, indicating significant intraday volatility as investors digest the results.

The most recent earnings (May 2026) saw relatively muted reactions with a 1.35% decline on Day 0 and 2.16% decline on Day +1, despite the strong earnings beat. This subdued response contrasts with more dramatic moves in prior quarters, such as the November 2024 report that triggered a 7.21% Day 0 decline. The directional pattern is mixed, with no clear bias toward post-earnings gains or losses, though the stock has shown a tendency for larger Day +1 ranges as the market fully processes the implications.

Investors should prepare for potential moves in the 3-7% range based on historical patterns, with the possibility of wider swings if results or guidance significantly deviate from expectations.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 4.53% for the upcoming earnings, which sits comfortably within the historical range but slightly above the average Day 0 move of 3.41% and Day +1 move of 3.30%. This suggests options traders are anticipating a fairly typical earnings reaction, though the 10-day timeframe to expiration (August 21) means the implied move captures more than just the immediate post-earnings session.

Part 3: What Analysts Are Saying

Analyst sentiment on IMNM is overwhelmingly bullish, with the consensus rating at 4.87 out of 5.00 — firmly in Strong Buy territory. The analyst community consists of 14 Strong Buys, 0 Moderate Buys, 1 Hold, 0 Moderate Sells, and 0 Strong Sells among the 15 analysts covering the stock. This represents one of the most lopsided bullish consensuses possible, with 93% of analysts rating the stock a Strong Buy.

The average price target of $35.77 implies 36.3% upside from the current price of $26.25, with individual targets ranging from a low of $30.00 (+14.3% upside) to a high of $40.00 (+52.4% upside). The relatively tight range of price targets suggests broad agreement on valuation methodology and probability-weighted outcomes, despite the inherent uncertainty in clinical-stage biotech investing.

Analyst sentiment has remained unchanged over the past month, with the same 14-0-1 Strong Buy/Hold split and identical average recommendation of 4.87. This stability suggests analysts are maintaining conviction in their bullish thesis heading into the Q2 report, likely reflecting confidence in the pipeline and platform rather than near-term financial performance. The lack of any sell ratings is notable and indicates the analyst community sees limited downside risk relative to the potential upside if clinical programs succeed.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a Buy signal at 72%, unchanged from last week but significantly improved from 40% Buy a month ago. This strengthening technical picture reflects the stock's recent momentum as it has climbed above all key moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates powerful near-term momentum heading into earnings
• Medium-term (Hold): Neutral reading suggests some consolidation may be needed in the intermediate timeframe
• Long-term (100% Buy): Strong buy signal reflects a well-established uptrend in the longer-term picture

Trend Characteristics: The combination of Average strength with Strongest direction suggests the stock is in a clearly defined uptrend, though momentum may not be at extreme levels that would signal overbought conditions.

The stock is currently trading at $26.25, positioned above all major moving averages: the 5-day ($25.66), 10-day ($24.53), 20-day ($23.53), 50-day ($21.68), 100-day ($21.91), and 200-day ($21.29). This complete alignment with price above all moving averages is a classically bullish technical setup, indicating strong momentum across all timeframes. The progressive stacking of moving averages (shorter-term above longer-term) confirms the uptrend structure.

The stock's 23.3% gain above its 200-day moving average represents substantial appreciation in recent months, potentially leaving it vulnerable to profit-taking if earnings disappoint. However, the technical setup is clearly supportive heading into the report, with momentum indicators aligned positively and no obvious resistance levels until the analyst price target zone around $35-36. The key risk is that the strong technical picture has already priced in positive expectations, meaning even an in-line report might not provide further catalyst for gains. Conversely, any disappointment could trigger a sharp reversal given the extended nature of the recent rally.